Clinical trials: Sadness
Seasonal Affective Disorder (SAD), Winter Depression
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Major depression is a highly prevalent, chronic, and debilitating mental health problem with significant social cost that poses a tremendous economic burden.
- Conditions
- Seasonal Affective Disorder (SAD), Winter Depression, Major Depressive Disorder, Recurrent, With Seasonal Pattern
- Trial name
- NCT01714050
- Testing
- Cognitive-Behavioral Therapy (CBT), Light Therapy (LT)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Vermont
Social Anxiety Disorder (SAD), Oppositional Defiant Disorder
ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence
Social functioning, fundamental to adolescent's development and mental health, may be impaired by polarizing problematic social functioning, namely externalizing symptoms manifested by Oppositional Defiant Disorder and…
- Trial name
- ACTsocially (NCT07456631)
- Testing
- ACTsocially
- Where
- Portugal
- Volunteers
- 54 people
- Sponsor
- University of Coimbra
Healthy Adult Male Volunteers
Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers
This study is planned to investigate the safety, tolerability, and pharmacokinetics when a single intravenous dose of MT-3534 or a placebo is given to healthy adult male volunteers.
- Trial name
- NCT06482346
- Testing
- MT-3534
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Bacterial Infections
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults
This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult…
- Trial name
- NCT04578873
- Testing
- QPX7831
- Where
- 2 sites in United States, Australia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Safety, Tolerability
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT07285967
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Cystic Fibrosis
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and…
- Trial name
- NCT04926701
- Testing
- ETD001 single dose, ETD001 multiple twice daily doses, ETD001 multiple once daily doses
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD)
Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders
Background Anxiety disorders are the most prevalent psychiatric disorders around the world. Effective treatment consists of pharmacotherapy or psychological treatment based on cognitive-behavioral therapy (CBT) and these…
- Conditions
- Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Posttraumatic Stress Disorder (PTSD)
- Trial name
- NCT06937892
- Testing
- Transdiagnostic metacognitive therapy, Disorder-specific cognitive-behavioral therapy
- Where
- Sweden
- Volunteers
- 86 people
- Sponsor
- Karolinska Institutet
Stage, Prostate Cancer
Sulforadex in Healthy Volunteers SAD
To determine the safety and tolerability of single escalating doses of Sulforadex® in healthy male volunteers.
- Trial name
- NCT01948362
- Testing
- Sulforadex, Alpha cyclodextrin
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Evgen Pharma
Healthy
Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)
This is a single center, open label, randomized, parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of obeticholic acid (OCA).
- Trial name
- NCT01933503
- Testing
- OCA 5 mg, OCA 10 mg, OCA 25 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Intercept Pharmaceuticals
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Social Anxiety Disorder (SAD)
The Covideo Study - a Trial of Cognitive Therapy for Social Anxiety Disorder in Youth, Comparing Screen to Office Delivery
The main goal of this clinical trial is to examine screen delivery as an alternative for offering cognitive therapy to youth with social anxiety.
- Trial name
- Covideo (NCT06901128)
- Testing
- cognitive therapy
- Where
- 5 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Sykehuset Innlandet HF
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Resistant Hypertension
JX09 SAD/MAD in Healthy Participants
This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09…
- Trial name
- NCT06183671
- Testing
- JX09
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Ji Xing Pharmaceuticals Australia Pty Ltd
Social Anxiety Disorder (SAD)
Interpretation Bias Modification Training for Social Anxiety Disorder
The overall goal of the current study is to develop and evaluate a computerized interpretation bias modification (IBM) training for treating social anxiety disorder (SAD).
- Trial name
- SAD (NCT07753538)
- Testing
- Interpretation Bias Modification Training, Stress Management Psychoeducation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Milwaukee
Healthy Volunteer Study
A Study of AST-008 in Healthy Subjects
AST-008 will be dosed subcutaneously to healthy volunteers in a combined SAD/MAD study to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics.
- Trial name
- NCT03086278
- Testing
- AST-008
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Exicure, Inc.
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Seasonal Affective Disorder, Major Depressive Disorder
Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD
Seasonal Affective Disorder (SAD) is a subtype of Major Depressive Disorder, characterized by a recurrent temporal relationship between the season of year, the onset and the remission of a major depressive episode.
- Conditions
- Seasonal Affective Disorder, Major Depressive Disorder, Neuroimaging
- Trial name
- NCT03313674
- Testing
- Bright Light Therapy
- Where
- Canada
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Chemotherapy-induced Diarrhea
A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of orally administered SK10 powders in healthy adult subjects at three dose levels, following single and multiple doses.
- Trial name
- NCT06026397
- Testing
- SK10
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.